87 related articles for article (PubMed ID: 27492661)
1. Calls to suspend European sales of erlotinib for lung cancer.
Tanday S
Lancet Respir Med; 2016 Sep; 4(9):691. PubMed ID: 27492661
[No Abstract] [Full Text] [Related]
2. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.
Takeda M; Okamoto I; Nakagawa K
Lung Cancer; 2015 Apr; 88(1):74-9. PubMed ID: 25704957
[TBL] [Abstract][Full Text] [Related]
3. Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis.
Arbitrio M; Di Martino MT; Barbieri V; Agapito G; Guzzi PH; Botta C; Iuliano E; Scionti F; Altomare E; Codispoti S; Conforti S; Cannataro M; Tassone P; Tagliaferri P
Cancer Chemother Pharmacol; 2016 Jan; 77(1):205-9. PubMed ID: 26607259
[TBL] [Abstract][Full Text] [Related]
4. Rapid improvement of psoriasis in a patient with lung cancer after treatment with erlotinib.
Goepel L; Jacobi A; Augustin M; Radtke MA
J Eur Acad Dermatol Venereol; 2018 Aug; 32(8):e311-e313. PubMed ID: 29430731
[No Abstract] [Full Text] [Related]
5. Effectiveness of erlotinib as a second line therapy for patients with epidermal growth factor receptor (EGFR) mutation in non-small cell lung cancer (NSCLC): our clinical experience.
Crvenkova S; Ivkovski Lj; Dimovski A; Kaeva B
Prilozi; 2012; 33(1):303-11. PubMed ID: 22983065
[TBL] [Abstract][Full Text] [Related]
6. Phase II Trial of Erlotinib in Elderly Patients with Previously Treated Non-small Cell Lung Cancer: Results of the Lung Oncology Group in Kyushu (LOGiK-0802).
Yamada K; Azuma K; Takeshita M; Uchino J; Nishida C; Suetsugu T; Kondo A; Harada T; Eida H; Kishimoto J; Eriguchi G; Takayama K; Nakanishi Y; Sugio K
Anticancer Res; 2016 Jun; 36(6):2881-7. PubMed ID: 27272800
[TBL] [Abstract][Full Text] [Related]
7. Four-Year Complete Remission in a Patient with Metastatic Epidermal Growth Factor Receptor-Mutated Lung Cancer Treated with Two Cycles of Erlotinib.
McCann B; Clark B
J Thorac Oncol; 2018 Jan; 13(1):e7-e8. PubMed ID: 29258671
[No Abstract] [Full Text] [Related]
8. Gastrointestinal perforations in patients treated with erlotinib: A report of two cases with fatal outcome and literature review.
Gass-Jégu F; Gschwend A; Gairard-Dory AC; Mennecier B; Tebacher-Alt M; Gourieux B; Quoix É
Lung Cancer; 2016 Sep; 99():76-8. PubMed ID: 27565918
[TBL] [Abstract][Full Text] [Related]
9. Waxing and Waning of MET Amplification in EGFR-Mutated NSCLC in Response to the Presence and Absence of Erlotinib Selection Pressure.
Womack JP; Varella-Garcia M; Camidge DR
J Thorac Oncol; 2015 Dec; 10(12):e115-8. PubMed ID: 26709484
[TBL] [Abstract][Full Text] [Related]
10. Erlotinib-associated bilateral anterior uveitis: resolution with posterior sub-Tenon's triamcinolone without erlotinib cessation.
Kirkpatrick CA; Almeida DR; Hornick AL; Chin EK; Boldt HC
Can J Ophthalmol; 2015 Oct; 50(5):e66-7. PubMed ID: 26455982
[No Abstract] [Full Text] [Related]
11. Erlotinib as first line treatment in a NSCLC patient with choroidal metastasis and with EGFR exon 19 deletion.
Kocoglu H; Karaca M; Turkay R; Tural D
J BUON; 2016; 21(3):754-5. PubMed ID: 27569104
[No Abstract] [Full Text] [Related]
12. Eyelash trichomegaly induced by erlotinib for metastatic lung cancer.
Chan JYY; Kwok TYT; Yuen HKL
Hong Kong Med J; 2021 Feb; 27(1):60.e1-60.e3. PubMed ID: 33568562
[No Abstract] [Full Text] [Related]
13. Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-old.
Bigot F; Boudou-Rouquette P; Arrondeau J; Thomas-Schoemann A; Tlemsani C; Chapron J; Huillard O; Cessot A; Vidal M; Alexandre J; Blanchet B; Goldwasser F
Invest New Drugs; 2017 Apr; 35(2):242-246. PubMed ID: 27796680
[TBL] [Abstract][Full Text] [Related]
14. Serum Concentration of Erlotinib and its Correlation with Outcome and Toxicity in Patients with Advanced-stage NSCLC.
Fiala O; Hosek P; Pesek M; Finek J; Racek J; Stehlik P; Sorejs O; Minarik M; Benesova L; Celer A; Nemcova I; Kucera R; Topolcan O
Anticancer Res; 2017 Nov; 37(11):6469-6476. PubMed ID: 29061834
[TBL] [Abstract][Full Text] [Related]
15. Duodenal Perforation Secondary to Erlotinib Therapy in a Patient With Non-Small Cell Lung Cancer.
Rafiullah ; Shah WS; Majid NA; Islam R
WMJ; 2017 Feb; 116(1):34-6. PubMed ID: 29099567
[TBL] [Abstract][Full Text] [Related]
16. Drug companies settle claim of misleading doctors on cancer survival data.
Dyer O
BMJ; 2016 Jun; 353():i3361. PubMed ID: 27307418
[No Abstract] [Full Text] [Related]
17. Erlotinib-induced reactive perforating collagenosis in a case of lung adenocarcinoma.
Jiang X; Song TT; Hao F
Indian J Dermatol Venereol Leprol; 2021 [SEASON]; 87(4):548-551. PubMed ID: 34219432
[No Abstract] [Full Text] [Related]
18. Plasma rich in growth factors for the treatment of rapidly progressing refractory corneal melting due to erlotinib in nonsmall cell lung cancer.
Guarnieri A; Alfonso-Bartolozzi B; Ciufo G; Moreno-Montañés J; Gil-Bazo I
Medicine (Baltimore); 2017 Jun; 96(22):e7000. PubMed ID: 28562552
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Skin Toxic Effects Associated With Gefitinib, Erlotinib, or Afatinib Treatment for Non-Small Cell Lung Cancer.
Chen KL; Lin CC; Cho YT; Yang CW; Sheen YS; Tsai HE; Chu CY
JAMA Dermatol; 2016 Mar; 152(3):340-2. PubMed ID: 26649681
[No Abstract] [Full Text] [Related]
20. [Effect of Erlotinib in 2nd and 3rd Line Anticancer Treatment in Patients with Squamous Cell Lung Cancer - Case Series].
Šatánková M; Brat K; Tomíšková M; Robešová B; Skřičková J
Klin Onkol; 2017; 30(2):131-135. PubMed ID: 28397509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
